Moradi Leila, Farhangiyan Zahra, Tangestani Makieh, Ashrafi Amir
Endocrinologist, Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Endocrinology Fellow, Department of Internal Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Maedica (Bucur). 2025 Jun;20(2):209-219. doi: 10.26574/maedica.2025.20.2.209.
Metabolic surgery (MS) has been demonstrated to achieve sustained weight loss with significant improvement of metabolic parameters, including reduced cardiovascular diseases and diabetes. This study aimed to evaluate the effect of MS on obesity outcomes and cardiovascular risk factors in Iranian non-diabetic obese patients.
This retrospective follow-up study included non-diabetic obese patients with a body mass index (BMI) of 30 kg/m 2 or higher who underwent MS (LSG or GB) in a single institution in Ahvaz, Iran, from April 2019 to March 2023. Of the 162 reviewed patients, 139 subjects (85.80%) who completed one-year follow-up visits were included in this study. Medical history, anthropometric, biochemical parameters, comorbidities and Framingham risk score (FRS) were evaluated at baseline and annual visits after MS.
The mean weight and BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), FRS, lipid profile, liver enzymes and fasting blood glucose (FBS) were significantly improved 12 months postoperatively. The percentage of total weight loss (%TWL) and BMI loss (%BMI) was 30.32±8.14 and 30.32±8.14, respectively, at the one-year follow-up after surgery. At one-year follow-up, a significant resolution of hypertension and dyslipidemia was observed in 44.4% and 73.9% of patients, respectively, and this improvement was stable throughout the follow-up period, with no significant difference between procedures. The type of MS had no effect on changes in weight and BMI at one-year and long-term follow-up after surgery (P>0.05), except the mean weight loss was greater with RYGB than LSG at one-year follow-up.
代谢手术（MS）已被证明能实现持续减重，并显著改善代谢参数，包括降低心血管疾病和糖尿病风险。本研究旨在评估代谢手术对伊朗非糖尿病肥胖患者肥胖结局和心血管危险因素的影响。
这项回顾性随访研究纳入了2019年4月至2023年3月期间在伊朗阿瓦士的一家机构接受代谢手术（腹腔镜袖状胃切除术[LSG]或胃旁路术[GB]）的体重指数（BMI）为30kg/m²或更高的非糖尿病肥胖患者。在162例接受评估的患者中，139例（85.80%）完成了一年随访，被纳入本研究。在代谢手术前的基线和术后每年随访时评估病史、人体测量学、生化参数、合并症和弗雷明汉风险评分（FRS）。
术后12个月，平均体重、BMI、收缩压（SBP）、舒张压（DBP）、FRS、血脂谱、肝酶和空腹血糖（FBS）均有显著改善。术后一年随访时，总体重减轻百分比（%TWL）和BMI降低百分比（%BMI）分别为30.32±8.14和30.32±8.14。在一年随访时，分别有44.4%和73.9%的患者高血压和血脂异常得到显著缓解，且这种改善在整个随访期间保持稳定，不同手术方式之间无显著差异。代谢手术类型对术后一年和长期随访时体重及BMI的变化无影响（P>0.05），但在一年随访时，胃旁路术（RYGB）的平均体重减轻幅度大于腹腔镜袖状胃切除术（LSG）。
